| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.049 | 0.3 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.3 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.047 | 0.3 |